Please enable JavaScript to continue using this application.

Compare $INBX vs $SNDX | Chartloom

Compare

$INBX vs $SNDX

Inhibrx Biosciences Inc · Syndax Pharmaceuticals Inc

INBX

Inhibrx Biosciences Inc

SNDX

Syndax Pharmaceuticals Inc

Compare $INBX vs $SNDX

Comparing Inhibrx Biosciences Inc and Syndax Pharmaceuticals Inc

INBXInhibrx Biosciences Inc

SNDXSyndax Pharmaceuticals Inc

INBXInhibrx Biosciences Inc

Market cap

$1.39B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

26.6%

52W performance

182.7%

FCF yield

-9.5%

SNDXSyndax Pharmaceuticals Inc

Market cap

$1.51B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

222.7%

YTD performance

-20.2%

52W performance

3.0%

FCF yield

-14.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INBX

SNDX

Detailed metrics comparison

INBX

Inhibrx Biosciences Inc

SNDX

Syndax Pharmaceuticals Inc

Market Cap

INBX$1.39B

SNDX$1.51B

Enterprise Value

INBX$1.44B

SNDX$1.76B

Price

INBX$95.01

SNDX$16.99

P/E Ratio

INBXN/A

SNDXN/A

P/S Ratio

INBX1,019.62x

SNDX5.97x

EV/Sales

INBX1,050.29x

SNDX6.97x

EV/EBITDA

INBX0.85x

SNDX1,613.51x

P/B Ratio

INBX178.59x

SNDX104.09x

P/FCF Ratio

INBXN/A

SNDXN/A

EV/FCF

INBX-10.89x

SNDX-7.96x

PEG Ratio

INBXN/A

SNDXN/A

Forward P/E (NTM)

INBXN/A

SNDXN/A

Forward P/S (NTM)

INBXN/A

SNDXN/A

Revenue (TTM)

INBX$0

SNDX$252M

Revenue Growth (YoY)

INBX-100.0%

SNDX222.7%

Forward Rev Growth

INBX282.8%

SNDX41.0%

Gross Margin (TTM)

INBX0.0%

SNDX95.8%

Operating Margin (TTM)

INBX0.0%

SNDX0.0%

EBITDA Margin (TTM)

INBX0.0%

SNDX-77.0%

Net Margin (TTM)

INBX0.0%

SNDX-87.5%

FCF Margin (TTM)

INBXN/A

SNDX-87.6%

Net Income (TTM)

INBX$-138M

SNDX$-221M

FCF (TTM)

INBX$-132M

SNDX$-221M

EPS (TTM)

INBX-$8.82

SNDX-$2.48

ROE (TTM)

INBX-26956.0%

SNDX-37294.0%

ROA (TTM)

INBX-8348.0%

SNDX-3911.0%

ROIC (TTM)

INBX-9241.0%

SNDX-4756.0%

Cash

INBX$133M

SNDX$336M

Debt

INBX$176M

SNDX$588M

Net Cash/Debt

INBX$-43M

SNDX$-252M

Current Ratio (TTM)

INBX5.07x

SNDX6.77x

Quick Ratio (TTM)

INBX4.76x

SNDX6.32x

Debt/Equity (TTM)

INBX12.58x

SNDX38.95x

Debt/Assets (TTM)

INBX0.0%

SNDX0.0%

Interest Coverage (TTM)

INBXN/A

SNDXN/A

Net Debt/EBITDA (TTM)

INBX0.00x

SNDX0.00x

Beta

INBX3.17

SNDX0.40

52W Performance

INBX182.7%

SNDX3.0%

YTD Performance

INBX26.6%

SNDX-20.2%

% from 52W High

INBX-38.8%

SNDX-33.6%

% from 52W Low

INBX237.4%

SNDX30.8%

Asset Turnover (TTM)

INBX0.01x

SNDX0.45x

FCF Yield (TTM)

INBX-9.5%

SNDX-14.7%

Earnings Yield (TTM)

INBX-9.9%

SNDX-14.7%

Dividend Yield (TTM)

INBXN/A

SNDXN/A

Rule of 40

INBX-100.0

SNDX135.1

EV/GP/RG

INBXN/A

SNDX0.15

Ticker research

View INBX research View SNDX research

Metric	INBX Inhibrx Biosciences Inc	SNDX Syndax Pharmaceuticals Inc
Market & Valuation
Market Cap	$1.39B	$1.51B
Enterprise Value	$1.44B	$1.76B
Price	$95.01	$16.99
P/E Ratio	N/A	N/A
P/S Ratio	1,019.62x	5.97x
EV/Sales	1,050.29x	6.97x
EV/EBITDA	0.85x	1,613.51x
P/B Ratio	178.59x	104.09x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.89x	-7.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$252M
Revenue Growth (YoY)	-100.0%	222.7%
Forward Rev Growth	282.8%	41.0%
Profitability
Gross Margin (TTM)	0.0%	95.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-77.0%
Net Margin (TTM)	0.0%	-87.5%
FCF Margin (TTM)	N/A	-87.6%
Net Income (TTM)	$-138M	$-221M
FCF (TTM)	$-132M	$-221M
EPS (TTM)	-$8.82	-$2.48
ROE (TTM)	-26956.0%	-37294.0%
ROA (TTM)	-8348.0%	-3911.0%
ROIC (TTM)	-9241.0%	-4756.0%
Financial Health
Cash	$133M	$336M
Debt	$176M	$588M
Net Cash/Debt	$-43M	$-252M
Current Ratio (TTM)	5.07x	6.77x
Quick Ratio (TTM)	4.76x	6.32x
Debt/Equity (TTM)	12.58x	38.95x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.17	0.40
52W Performance	182.7%	3.0%
YTD Performance	26.6%	-20.2%
% from 52W High	-38.8%	-33.6%
% from 52W Low	237.4%	30.8%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.45x
FCF Yield (TTM)	-9.5%	-14.7%
Earnings Yield (TTM)	-9.9%	-14.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	135.1
EV/GP/RG	N/A	0.15
Ticker research	View INBX research	View SNDX research

Valuation

P/S Ratio

SNDX

5.97x

INBX

1,019.62x

EV/FCF

INBX

-10.89x

SNDX

-7.96x

Growth & revenue

Revenue Growth TTM

SNDX

222.7%

INBX

-100.0%

Forward Revenue Growth

INBX

282.8%

SNDX

41.0%

Profitability & performance

Gross Margin

SNDX

95.8%

INBX

0.0%

ROE

INBX

-26956.0%

SNDX

-37294.0%

FCF Yield %

INBX

-9.5%

SNDX

-14.7%

52-Week Performance

INBX

182.7%

SNDX

3.0%

Detailed metrics comparison

INBX

Inhibrx Biosciences Inc

SNDX

Syndax Pharmaceuticals Inc

Market Cap

INBX$1.39B

SNDX$1.51B

Enterprise Value

INBX$1.44B

SNDX$1.76B

Price

INBX$95.01

SNDX$16.99

P/E Ratio

INBXN/A

SNDXN/A

P/S Ratio

INBX1,019.62x

SNDX5.97x

EV/Sales

INBX1,050.29x

SNDX6.97x

EV/EBITDA

INBX0.85x

SNDX1,613.51x

P/B Ratio

INBX178.59x

SNDX104.09x

P/FCF Ratio

INBXN/A

SNDXN/A

EV/FCF

INBX-10.89x

SNDX-7.96x

PEG Ratio

INBXN/A

SNDXN/A

Forward P/E (NTM)

INBXN/A

SNDXN/A

Forward P/S (NTM)

INBXN/A

SNDXN/A

Revenue (TTM)

INBX$0

SNDX$252M

Revenue Growth (YoY)

INBX-100.0%

SNDX222.7%

Forward Rev Growth

INBX282.8%

SNDX41.0%

Gross Margin (TTM)

INBX0.0%

SNDX95.8%

Operating Margin (TTM)

INBX0.0%

SNDX0.0%

EBITDA Margin (TTM)

INBX0.0%

SNDX-77.0%

Net Margin (TTM)

INBX0.0%

SNDX-87.5%

FCF Margin (TTM)

INBXN/A

SNDX-87.6%

Net Income (TTM)

INBX$-138M

SNDX$-221M

FCF (TTM)

INBX$-132M

SNDX$-221M

EPS (TTM)

INBX-$8.82

SNDX-$2.48

ROE (TTM)

INBX-26956.0%

SNDX-37294.0%

ROA (TTM)

INBX-8348.0%

SNDX-3911.0%

ROIC (TTM)

INBX-9241.0%

SNDX-4756.0%

Cash

INBX$133M

SNDX$336M

Debt

INBX$176M

SNDX$588M

Net Cash/Debt

INBX$-43M

SNDX$-252M

Current Ratio (TTM)

INBX5.07x

SNDX6.77x

Quick Ratio (TTM)

INBX4.76x

SNDX6.32x

Debt/Equity (TTM)

INBX12.58x

SNDX38.95x

Debt/Assets (TTM)

INBX0.0%

SNDX0.0%

Interest Coverage (TTM)

INBXN/A

SNDXN/A

Net Debt/EBITDA (TTM)

INBX0.00x

SNDX0.00x

Beta

INBX3.17

SNDX0.40

52W Performance

INBX182.7%

SNDX3.0%

YTD Performance

INBX26.6%

SNDX-20.2%

% from 52W High

INBX-38.8%

SNDX-33.6%

% from 52W Low

INBX237.4%

SNDX30.8%

Asset Turnover (TTM)

INBX0.01x

SNDX0.45x

FCF Yield (TTM)

INBX-9.5%

SNDX-14.7%

Earnings Yield (TTM)

INBX-9.9%

SNDX-14.7%

Dividend Yield (TTM)

INBXN/A

SNDXN/A

Rule of 40

INBX-100.0

SNDX135.1

EV/GP/RG

INBXN/A

SNDX0.15

Ticker research

View INBX research View SNDX research

Metric	INBX Inhibrx Biosciences Inc	SNDX Syndax Pharmaceuticals Inc
Market & Valuation
Market Cap	$1.39B	$1.51B
Enterprise Value	$1.44B	$1.76B
Price	$95.01	$16.99
P/E Ratio	N/A	N/A
P/S Ratio	1,019.62x	5.97x
EV/Sales	1,050.29x	6.97x
EV/EBITDA	0.85x	1,613.51x
P/B Ratio	178.59x	104.09x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.89x	-7.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$252M
Revenue Growth (YoY)	-100.0%	222.7%
Forward Rev Growth	282.8%	41.0%
Profitability
Gross Margin (TTM)	0.0%	95.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-77.0%
Net Margin (TTM)	0.0%	-87.5%
FCF Margin (TTM)	N/A	-87.6%
Net Income (TTM)	$-138M	$-221M
FCF (TTM)	$-132M	$-221M
EPS (TTM)	-$8.82	-$2.48
ROE (TTM)	-26956.0%	-37294.0%
ROA (TTM)	-8348.0%	-3911.0%
ROIC (TTM)	-9241.0%	-4756.0%
Financial Health
Cash	$133M	$336M
Debt	$176M	$588M
Net Cash/Debt	$-43M	$-252M
Current Ratio (TTM)	5.07x	6.77x
Quick Ratio (TTM)	4.76x	6.32x
Debt/Equity (TTM)	12.58x	38.95x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.17	0.40
52W Performance	182.7%	3.0%
YTD Performance	26.6%	-20.2%
% from 52W High	-38.8%	-33.6%
% from 52W Low	237.4%	30.8%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.45x
FCF Yield (TTM)	-9.5%	-14.7%
Earnings Yield (TTM)	-9.9%	-14.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	135.1
EV/GP/RG	N/A	0.15
Ticker research	View INBX research	View SNDX research